Pentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation

Abstract

IL-6 ‫مع‬ ‫إحصائي‬ ‫ومهم‬ ‫قوي‬ ‫ارتباط‬ hsCRP ‫مستويات‬ ‫مع‬ ‫وليس‬ ،IL-10‫و‬ ،IL-6‫و‬ ،cTnI ،p=0.006 ‫انحدار‬ ‫لتحليل‬ ً ‫وفقا‬ MACEs ‫مع‬ ‫مستقل‬ ‫ارتباط‬ ‫أي‬ ‫يظهر‬ ‫لم‬ ‫الذي‬ ‫املتغيرات.‬ ‫متعدد‬ ‫كوكس‬ IL-‫من‬ ‫أفضل‬ ‫للمصل‬ ‫منذره‬ ‫عالمة‬ ‫يكون‬ ‫قد‬ TPTX3 ‫اخلالصة:‬ .BMS-PCI ‫بعد‬ MACEs ‫لل‬ CRP ‫عالية‬ ‫حساسية‬ ‫أو‬ 10، IL-6 ‫املرضى‬ ‫لهؤالء‬ ‫أفضل‬ ‫للمخاطر‬ ‫الطبقي‬ ‫التقسيم‬ ‫جعل‬ ‫على‬ ‫يساعد‬ ‫قد‬ .BMS-PCI ‫ـ‬ ‫ل‬ ‫يخضعون‬ ‫الذين‬ Objectives: To assess the prognostic value of pentraxin 3 (PTX3) in patients with ST-elevation myocardial infarction (STEMI) after bare-metal stent (BMS) implantation. Original Articles Methods: In this prospective study, PTX3, interleukin (IL-6), IL-10, high-sensitivity c-reactive protein (hsCRP), and cardiac troponin I (cTnI) plasma values were determined before and 24 hours after BMS implantation in 97 consecutively enrolled patients with STEMI who were admitted to University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina between February 2016 and February 2017. Patients were followed for 24 months to assess major adverse cardiovascular events (MACEs). Results: At 24 hours after percutaneous coronary intervention (PCI), plasma values of PTX3, IL-6, hsCRP, and cTnI were significantly increased; and IL-10 levels were significantly decreased compared with the values determined before PCI. Patients with MACEs had significantly higher plasma PTX3 levels at 24 hours after BMS-PCI than in patients without MACEs. Patients with PTX3 plasma values ≥5042 ng/ml had a significantly higher risk of MACEs than patients with PTX3 levels <5.042 ng/mL. Pentraxin 3 levels exhibited strong and significant correlations with IL-6 and IL-10 levels. Pentraxin 3, cTnI, and IL-6, but not hsCRP levels have showed independent association with MACEs, according to the multivariate Cox regression analysis. Conclusion: Pentraxin 3 might be better serum prognostic marker than IL-6, IL-10 or high sensitivity CRP for MACEs after BMS-PCI. It might help to make better risk stratification of those patients who are undergoing BMS-PCI.

Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies

“…One study reported outcome data in patients with STEMI and NSTE-ACS separately ( 15 ) and these datasets were independently included in the meta-analysis. Plasma PTX-3 were measured with ELISA in all of the included studies and various cutoff values were used to compare the incidence of adverse outcomes according to the PTX-3 level such as medians ( 16 , 19 , 24 , 28 ), tertiles ( 13 , 14 , 17 , 21 , 23 ), quartiles ( 15 , 20 , 25 , 26 ), and cutoff values derived by measuring of normal controls ( 18 ) and from the receiver operating characteristic (ROC) analysis ( 22 , 27 ). The mean follow-up durations varied between 1 and 60 months.…”

“…Of these, 19 relevant records were further excluded for the reasons given in Figure 1. Finally, 16 cohort studies were obtained for the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28).…”

“…Overall, 16 cohort studies including 11,007 adults with CAD were included in the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). These studies were published between 2004 and 2021 and most of the studies were prospective (13)(14)(15)(16)(17)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28), except one study, which was retrospective (18).…”

“…Overall, 16 cohort studies including 11,007 adults with CAD were included in the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). These studies were published between 2004 and 2021 and most of the studies were prospective (13)(14)(15)(16)(17)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28), except one study, which was retrospective (18). For the subtype of CAD, four studies included patients with stable CAD (13,17,19,20), while the other studies included patients with ACS [7 patients with STEMI (14, 21-25, 27), two patients with NSTE-ACS (16,18), and three patients with both STEMI and NSTE-ACS (15,26,28)].…”

“…Besides, the authors were also unable to determine whether other study characteristics could affect the potential predictive efficacy of PTX-3 such as follow-up durations and adjustment of C-reactive protein (CRP), a well-known inflammatory indicator of CAD ( 29 ). Since then, many cohort studies of a similar field have been published ( 13 , 24 – 28 ). Accordingly, we aimed to perform an updated meta-analysis to systematically evaluate the potential prognostic role of PTX-3 in CAD, multiple predefined subgroup analyses were also performed to evaluate whether the outcome differed according to the subtype of CAD, follow-up duration, and with or without adjustment of CRP.…”